Royalty Pharma plc Class A Ordinary Shares (RPRX)
RPRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$56.57
-2.09% on the day
Market cap
$32.5B
Large cap
Revenue · 2025
$2.4B
+5.1% on 2024
Net income · 2025
$770.9M
32.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | RPRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001802768 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | X0 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.4B |
| Net income | $770.9M |
| Operating income | $1.6B |
| Net margin | 32.4% |
| Operating margin | 65.6% |
| Revenue growth | +5.1% |
| Cash | $618.7M |
| Total assets | $19.6B |
| P/E (computed) | 42.2× |
| P/S (computed) | 13.7× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2025-09-03 |
| Latest annual report | 10-K | 2026-02-11 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-08-05 |
| Latest proxy | DEFA14A | 2026-04-10 |
Source: SEC EDGAR submissions feed, 633 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.7% |
| 1 month | +0.6% |
| 3 months | +0.5% |
| Year to date | +52.3% |
| 1 year | +66.1% |
| From 52-week high | -8.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ZTS | Zoetis Inc. | $74.30 | -1.78% | $30.7B |
| ALNY | Alnylam Pharmaceuticals Inc. | $223.82 | -1.41% | $29.9B |
| ONC | BeOne Medicines Ltd. | $349.08 | -0.38% | $39.7B |
| ROIV | Roivant Sciences Ltd. Common Shares | $33.35 | -3.58% | $24.1B |
| UTHR | United Therapeutics Corporation | $543.40 | -1.22% | $23.3B |
| GMAB | Genmab A/S ADS | $36.57 | -2.14% | $22.8B |
| TEVA | Teva Pharmaceutical Industries Limited | $41.25 | +0.19% | $48.1B |
| INSM | Insmed Incorporated | $96.79 | -1.80% | $21.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier